Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael


Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles


Novavax Will Seek a Combo Vaccine for Flu and COVID-19

The company has tasked a team of executives first with getting its flu vaccine candidate approved, and then with combining it with the coronavirus vaccine that it's developing.


The Top 2 Contrarian Stocks to Buy Right Now

The stocks of Amarin and Clean Energy Fuels are down 90% off their highs -- but both could bounce back in a big way.


2 Game-Changing Stocks That Are Better Buys Than Snowflake

These two companies are growing revenues faster than Snowflake, and they're way more profitable.


EU Regulators Undertake Rolling Review of Pfizer and BioNTech Vaccine Candidate

Pfizer and BioNTech will share the data from their phase 3 clinical trial with the European Medicines Agency as it comes in.


Will Big Pharma Acquire Novavax?

The value of this vaccine specialist has shifted dramatically because of the coronavirus.


Nano-X Announces Live Demonstration of Its ARC Device

Stock rallies 37% on the news.


Hibbett Sports Is Crushing It

The 75-year-old sports retailer is growing revenue by 75%.


Why Are People Shorting Nano-X?

After suffering two brutal short attacks, Nano-X stock has dropped 50% in a couple of weeks. Should investors flee, or is this actually a buying opportunity?


Better Buy: Amazon vs. Ulta Beauty

Amazon's stock has walloped Ulta over the last few years. Will this dominance continue?


Should Teladoc Be Worried About GoodRx?

Just days after its IPO, GoodRx already has a valuation that rivals that of Teladoc Health. Can the fast-growing upstart leverage its popularity to become the new king of virtual healthcare?


Will Celsius Be the Next Monster Beverage?

The stock of the high-flying drink is up 500% over the last year. How high can it go?


3 Top Biotech Picks for 2025

The opportunity is vast for Ontrak, Nano-X Imaging, and Zymeworks.


If You Invested $5,000 in Vaxart in the March Market Crash, This Is How Much You'd Have Today

Shares of the vaccine developer have shot up as it pursues a preventative COVID-19 treatment.


Grail, Backed by Jeff Bezos and Bill Gates, Files for IPO

The company seeks to detect cancer from a simple blood test.


6 Companies Racing to Mass-Produce a Coronavirus Vaccine in 2021

These healthcare companies have had plenty of help in building the manufacturing capacity needed to produce billions of vaccine doses.


What Is Afterpay and Why Does Shopify Want Its Business?

Afterpay introduced the "buy now, pay later" model that has taken Australia by storm. Now Shopify is partnering with a competitor to take it on.


Why Farfetch Is Not Afraid of Amazon

Farfetch is the top dog and first mover in helping high fashion brands sell clothes online. Now Amazon wants a piece of that market.


Why Novavax's Coronavirus Vaccine Might Be First to Market

The key variable in this race is not the phase 3 trial, but which company has enough positive data for an Emergency Use Authorization.


These 5 Healthcare Stocks Are the Biggest Winners in 2020

It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.


AstraZeneca Might Receive Emergency Use Authorization for Its Coronavirus Vaccine

One report suggests that the U.K.-based company might win the coronavirus vaccine race in the U.S.